Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Current Deferred Revenue (2016 - 2025)

Fate Therapeutics' Current Deferred Revenue history spans 14 years, with the latest figure at $381000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 3.05% year-over-year to $381000.0; the TTM value through Dec 2025 reached $381000.0, down 3.05%, while the annual FY2025 figure was $381000.0, 3.05% down from the prior year.
  • Current Deferred Revenue reached $381000.0 in Q4 2025 per FATE's latest filing, up from $5000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $42.2 million in Q4 2022 to a low of $5000.0 in Q3 2025.
  • Average Current Deferred Revenue over 5 years is $12.8 million, with a median of $1.8 million recorded in 2023.
  • Peak YoY movement for Current Deferred Revenue: surged 619.57% in 2021, then tumbled 99.17% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $21.5 million in 2021, then skyrocketed by 96.56% to $42.2 million in 2022, then plummeted by 98.38% to $685000.0 in 2023, then crashed by 42.63% to $393000.0 in 2024, then fell by 3.05% to $381000.0 in 2025.
  • Per Business Quant, the three most recent readings for FATE's Current Deferred Revenue are $381000.0 (Q4 2025), $5000.0 (Q3 2025), and $212000.0 (Q1 2025).